2^nd World Congress on Drug Discovery and Drug Design November 09-10, 2020 Tokyo, Japan

Track 1: Drug Discovery

Potential new medicines are identified by Drug discovery process. Identification of candidates, synthesis, characterization, screening and assays for therapeutic efficacy all are involves in process of drug discovery.

Track 2: Drug Designing and Development

Inventive process of finding new medications based on the knowledge of biological target is called Drug design. Drug design also known as rational drug design. Bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery is called Drug development.

Track 3: Drug Delivery Devices

Drug product formulation is at the core of Particle Sciences. Particle Sciences believes formulation is a data driven science and we follow a methodical efficient approach. Particle Sciences uses standard approaches such as liquids, suspensions, extended and controlled release polymers, emulsions, self-emulsifying systems and a host of others.  A new class of drug delivery device which can inject doses far larger than today’s syringes or auto injectors has developed i.e., Bolus Injectors having the capability to deliver more than 1 ml of a drug subcutaneously in a simple, reliable, and inexpensive manner. In the last 12 years, drugs have been delivered using self-regulated and Nano-technology systems.

Track 4: Molecular Modelling in Drug Designing

Molecular modelling has become a valuable and essential tool to medicinal chemists in the drug design process. Molecular modelling designates the generation, manipulation or representation of three-dimensional structures of molecules and associated physio-chemical properties. The aim of this review is to give an outline of studies in the field of medicinal chemistry in which molecular modelling has helped in the discovery process of new drugs. Molecular modelling is expanded over the last decades from a tool to visualize 3Dimensional database.

Track 5: Pharmacovigilance

The process of detection, Assessment, understanding and prevention of side effects of drugs is called Drug safety also known as Pharmacovigilance. Drug carry a number of risks and understanding the science behind adverse drug reactions can help increase the safety of new medicines. The role of Good Pharmacovigilance Practice and Pharmacoepidemiology in Risk Management is mainly to increase the probability of beneficial effects of a drug in a population than the probability of adverse effects and to maintain the Good Reporting Practices by avoiding the major problems in risk management.

Track 6: Pharmaceutical Drug Discovery and Nanotechnology

Nanotechnology has now introduced to develop medicine. Nanotechnology contains the use of materials with essential length scales in the nanometre measurement which demonstrate significantly changed properties associated to micron structured materials. Such materials can include particles, fibres, grain sizes, etc. This session highlighted the progressions nanotechnology is making in medicine in such fields as disease prevention, diagnosis, and treatment including (but not limited to) drug delivery, tissue engineering, implants, sensors, cancer treatment an (but not limited to) drug delivery, tissue engineering, transplants, sensors, cancer treatment, and toxic.

Track 7: Computer Aided Drug Design-CADD

Utilization of computational procedures in drug revelation and advancement process is quickly picking up in fame, usage and appreciation. Diverse terms are being connected to this region, including Computer-Aided Drug Design(CADD), computational medication plan, Computer-Aided Molecular Design (CAMD), Computer-Aided Molecular Modelling (CAMM), discerning medication outline, in the silico sedate plan, computer-aided rational drug design.

Track 8: Biopharmaceutical Drug Design and Development

Drug design is an inventive process of finding new medications of a biological target which frequently but not necessarily relies on computer modelling techniques use of high throughput screening techniques to analyse a new compounds, both by synthetic and natural, as novel drugs. Regrettably, this approach has yielded very little achievement in the field of anti-infective drug discovery. The identification of both molecular targets that are essential for the survival of the pathogen, and compounds that are active on intact cells, is a challenging task. Even more formidable, however, is the fulfilment for appropriate potency levels and suitable pharmacokinetics, in order to achieve efficacy in small animal disease models.

Track 9: Biomarkers in Drug Design

Biomarkers of disease play an important role in medicine and have begun to assume a greater role in drug discovery and development Biomarkers increase the success rate of drug development programmes and thereby accelerate the availability of new therapeutics. Robust and validated biomarkers are needed to improve diagnosis, monitor drug activity and therapeutic response and guide the development of safer and targeted therapies for various chronic diseases.

Track 10: Medicinal Chemistry & Drug Discovery

Medicinal chemistry  are disciplines at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various other biological specialties, where they are involved with design, chemical synthesis and development for market of pharmaceutical agents, or bio-active molecules (drugs). Drug delivery refers to approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect.

Track 11: Proteomics & Bioinformatics in Drug Discovery

Proteomics, the large-scale analysis of proteins, contributes expressively to our understanding of gene function in the post-genomic era. Proteomics can be divided into three main areas: (1) protein micro-characterization for large-scale certification of proteins and their post-translational changes; (2) 'differential display' proteomics for comparison of protein levels with potential application in a extensive range of diseases; and (3) studies of protein–protein interactions using methods such as mass spectrometry or the yeast two-hybrid system. Proteomics technologies are under nonstop progresses and new skills are introduced. Nowadays high quantity acquisition of proteome data is possible.

Drug research and development is a long-term and complicated process with the involvement of multidisciplinary, multi-sector cooperation and regulations of the Food and Drug Administration (FDA). It is of high risk, high cost, high benefit and time-consuming. Therefore, the drug administration and management is extremely necessary and useful. We discussed the whole process including laboratory study, target determination, drug discovery and screening, leading compound and optimization, preclinical and clinical trials, FDA approval and marketing.

According to an international research company, in 2012 the size of the global pharmaceutical market reached $940 billion. In monetary terms it grew by 6%. In the future the sector is expected to grow at no less than 3% to 4% a year and if this happens the market will reach $1.2 trillion in 2016 and up to $1.5 trillion by 2020. Another research company, Business Monitor International, has made a forecast for the size and geographical composition of the global pharmaceutical market in 2020. However by 2020, the Asian pharmaceutical market has a share of 33% in global pharmaceutical market.

The Asia Pacific is the fastest-growing region, due to the presence of skilled labor at an affordable cost, the rise in disposable income, and favorable government policies that are contributing to the market growth. There has also been phenomenal growth in the outsourcing companies in the Chinese region, over the last decade, which has complemented the restructuring of the R&D that has taken place. Thus, owing to the large deals of pharmaceutical companies and more number of research being done, the market for drug discovery is expected to grow.

Global “Drug Discovery Market” 2019 Industry Research Report is a professional and in-depth study on the current state of the Global Drug Discovery industry. This report focuses on the global Drug Discovery status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Drug Discovery development in United States, Europe and China.

In 2018, the global Drug Discovery market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

Importance & Scope:

Thanks to advances in science and technology, the research based pharmaceutical industry is entering an exciting new era in medicines development. According to an international research company, in 2012 the size of the global pharmaceutical market reached $940 billion. In monetary terms it grew by 6%. In the future the sector is expected to grow at no less than 3% to 4% a year and if this happens the market will reach $1.2 trillion in 2016 and up to $1.5 trillion by 2020. Another research company, Business Monitor International, has made a forecast for the size and geographical composition of the global pharmaceutical market in 2020. However by 2020, the Asian pharmaceutical market has a share of 33% in global pharmaceutical market.

Why Tokyo, Japan?

Tokyo is Japan's capital and the world's most populous metropolis. It is also one of Japan's 47 prefectures, consisting of 23 central city wards and multiple cities, towns and villages west of the city center. The Izu and Ogasawara Islands are also part of Tokyo. It has neon and salaryman crowds, packed trains, cutting-edge architecture and futuristic technology. But it also has ancient shrines, plant-covered wooden houses, cycling grannies, old-school sweet shops and village-like lanes.

Japan continues to be one of the largest pharmaceutical markets in the world despite a challenging business landscape due to demographics. According to the latest official figures from the Ministry of Health, Labor and Welfare (MHLW)’s Annual Pharmaceutical Production Statistics, the Japanese market for prescription and nonprescription pharmaceuticals in 2015 totaled $88 billion (up 10.7% from 2014 in yen terms). More than 90% of the total market consists of prescription pharmaceuticals. Imports of foreign pharmaceuticals accounted for approximately 38% of the total Japanese market in 2015. Japan’s total imports of U.S. pharmaceuticals totaled $5.7 billion in 2015, a 6% market share. However, the total market share of U.S.-origin pharmaceuticals, i.e., including local production by US firms and US-owned compounds licensed to Japanese manufacturers approaches 20%. The size of the market is expected to increase in a measured fashion for the foreseeable future due to continued demands for drugs from Japan’s aging population and the rising number of chronic and long-term diseases. However, in the short term, the market may see limited growth due to pricing environment which could become more challenging.

Contrary to these positive developments, strong financial pressure is simultaneously growing for the GOJ to contain healthcare spending in the country due to the rapid aging of Japan's population. In JFY 2014, national health expenditures hit another record at Yen 40.81 trillion (U.S.D 337.1 billion at U.S.D1=JPY121.05). Nearly 58.6%of all medical expenditures were for elderly patients over the age of 65. MHLW estimates that the healthcare expenditure will reach Yen 54 trillion by 2015. As a result, the GOJ is expected to continue addressing immediate budget short falls by cutting prices for pharmaceuticals. In late December 2016, the GOJ’s Council on Economic and Fiscal Policy (CEFP) and four Ministers announced a basic plan to overhaul the drug pricing mechanism. The basic plan calls for some significant changes from the current pricing system such as reviewing drug prices four times a year if the particular drug saw an expansion of market size due to indication additions; conducting drug price surveys every year from the current biennial cycle; and reviewing the pricing premium for the promotion of new drug development (so called ‘Price Premium System’) on a zero basis. The implementation of the Price Premium System in 2010 was a major positive development for pharmaceutical firms as it provides a predictable and stable pricing environment for innovative drugs throughout the life of the patent. Since the premium pricing system was implemented, there has been a significant decrease in the submission lag and a significant increase in the number of drugs developed in Japan. As such, the “zero-based” review of the price maintenance premium may have significant implications for foreign drug makers with innovative drugs depending on the scope of revision. The GOJ began holding discussions on the details of the planned drug pricing overhaul in January 2017 with a framework of pricing reform to be drawn by the end of 2017.